We have not conducted experiments to determine whether Product No. SAB1404011, Monoclonal Anti-KRAS antibody, clone 4F3, will react with Human NRAS (UniProt P01111) and Human HRAS (UniProt P01112). However, based on the alignment data, there is a high probability of recognition, though we cannot guarantee it. In the comparison, the similarity between Human HRAS (UniProt P01112) and SAB1404011 KRAS monoclonal antibody, clone 4F3 is very high (96%), suggesting theoretical recognition. Similarly, the similarity between Human NRAS (UniProt P01111) and SAB1404011 KRAS monoclonal antibody, clone 4F3 is also very high (95%), indicating theoretical recognition.
价格与库存信息目前不能提供
推荐产品
产品名称
单克隆抗 KRAS 小鼠抗, clone 4F3, purified immunoglobulin, buffered aqueous solution
生物来源
mouse
偶联物
unconjugated
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
4F3, monoclonal
表单
buffered aqueous solution
分子量
antigen ~38.21 kDa
种属反应性
human
技术
capture ELISA: suitable
indirect ELISA: suitable
western blot: 1-5 μg/mL
同位素/亚型
IgG2aκ
NCBI登记号
UniProt登记号
运输
dry ice
储存温度
−20°C
靶向翻译后修饰
unmodified
基因信息
human ... KRAS(3845)
一般描述
c-K-Ras或KRAS（Kirsten大鼠肉瘤2病毒癌基因）是一种小的GTP结合蛋白。编码它的基因位于人染色体12p12.1上。KRAS有两个剪接变体，即KRASA和KRASB（KRAS原癌基因）。KRASA的表达仅限于特定组织，而KRASB广泛表达。
该基因是Kirsten ras癌基因同源物，来自哺乳动物ras基因家族，所编码的蛋白是小GTP酶超家族成员。单个氨基酸的取代造成了活化突变。所产生的转化蛋白与各种恶性肿瘤有关，包括肺腺癌、粘液性腺瘤、胰腺导管癌和结肠直肠癌。选择性剪接产生变体，编码两个同工型，在C末端区域不同。（由RefSeq提供）
免疫原
KRAS（NP_004976, 16 a.a.~ 125 a.a）带有GST标签的部分重组蛋白。仅GST标签的MW为26 KDa。
序列
KSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTV
序列
KSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTV
应用
小鼠抗KRAS单克隆抗体可用于蛋白质印迹。[1]
生化/生理作用
KRAS（Kirsten大鼠肉瘤-2病毒癌基因）突变已与早期直肠癌和结直肠癌相关。该蛋白在信号传导途径中起作用。
KRAS（kirsten大鼠肉瘤2病毒癌基因）与细胞表面受体（包括EGFR）结合后，通过从GDP结合状态循环到GTP结合状态，充当自灭活信号转导子。基因突变导致早期直肠癌预后不良。
外形
溶于pH7.4的磷酸盐缓冲盐水中的溶液
免责声明
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
David M Briere et al.
Molecular cancer therapeutics, 20(6), 975-985 (2021-03-17)
KRASG12C inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non-small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are needed. KRASG12C mutations are smoking-associated transversion mutations associated with high
Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer
Kwak MS, et al.
Medicine, 96(35) (2017)
KRAS G12C Drug Development: Discrimination between Switch II Pocket Configurations Using Hydrogen/Deuterium-Exchange Mass Spectrometry
Lu J, et al.
Structure, 25(9), 1442-1448 (2017)
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: a systematic review and meta-analysis.
Zhuang R, et al.
PLoS ONE, 12(8), e0182562-e0182562 (2017)
Jia Lu et al.
Structure (London, England : 1993), 25(9), 1442-1448 (2017-08-07)
KRAS G12C, the most common RAS mutation found in non-small-cell lung cancer, has been the subject of multiple recent covalent small-molecule inhibitor campaigns including efforts directed at the guanine nucleotide pocket and separate work focused on an inducible pocket adjacent
-
Could you verify if Product No. SAB1404011, Monoclonal Anti-KRAS antibody, has cross-reactivity with N-Ras and H-Ras?
1 answer-
Helpful?
-
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
